The improved bioactivity of LUV-TRAIL has been validated in a broad panel of human cancer cells derived from hematological malignancies [19,20,21], as well as epithelial cancer cells both in vitro and in vivo [22,23,24]. The gene discussed is TNFSF10; the disease is hematologic disorder.